Literature DB >> 26535024

Evaluation of Biosimilars for Formulary Inclusion: Factors for Consideration by P&T Committees.

C Lee Ventola.   

Abstract

P&T committees will play a key role in driving the adoption of biosimilars, which have unique characteristics compared with small-molecule generic drugs. Key elements of formulary review will include clinical parameters, product characteristics, and institutional considerations, which are among the issues covered in this article.

Year:  2015        PMID： 26535024      PMCID： PMC4606858     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  20 in total

Review 1.  Biosimilars and market access: a question of comparability and costs?

Authors:  Steven Simoens; Gilbert Verbeken; Isabelle Huys
Journal:  Target Oncol       Date:  2012-01-17       Impact factor: 4.493

2.  Innovation and Competition: Will Biosimilars Succeed?: The creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safety.

Authors:  Erwin A Blackstone; Joseph P Fuhr
Journal:  Biotechnol Healthc       Date:  2012

3.  The state of the art in the development of biosimilars.

Authors:  Mark McCamish; Gillian Woollett
Journal:  Clin Pharmacol Ther       Date:  2012-02-08       Impact factor: 6.875

4.  Challenges in the anticipation of biosimilars: how must a P&T committee gear up?

Authors:  Celynda Tadlock
Journal:  Manag Care Interface       Date:  2007-04

5.  Biosimilars: Implications for health-system pharmacists.

Authors:  Steven D Lucio; James G Stevenson; James M Hoffman
Journal:  Am J Health Syst Pharm       Date:  2013-11-15       Impact factor: 2.637

6.  President obama reopens debate on patented biologics: will the FDA quickly define an abbreviated pathway for biosimilars?

Authors:  Stephen Barlas
Journal:  P T       Date:  2011-04

7.  Formulary Selection Criteria for Biosimilars: Considerations for US Health-System Pharmacists.

Authors:  Niesha Griffith; Ali McBride; James G Stevenson; Larry Green
Journal:  Hosp Pharm       Date:  2014-10

8.  Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.

Authors:  Benjamin P Falit; Surya C Singh; Troyen A Brennan
Journal:  Health Aff (Millwood)       Date:  2015-02       Impact factor: 6.301

9.  Biosimilars might not measure up to health plan expectations.

Authors:  Tom Reinke
Journal:  Manag Care       Date:  2012-10

10.  Biosimilars: company strategies to capture value from the biologics market.

Authors:  Bruno Calo-Fernández; Juan Leonardo Martínez-Hurtado
Journal:  Pharmaceuticals (Basel)       Date:  2012-12-12
View more
  6 in total

1.  Effect on Patients' Outcomes of a Change to Biosimilar Filgrastim Product in Autologous Stem Cell Mobilization.

Authors:  Jennifer Fenna; Micheal Guirguis; Caroline Ibrahim; Neeta Shirvaikar; Irwindeep Sandhu; Sunita Ghosh; Melissa Jenkins
Journal:  Can J Hosp Pharm       Date:  2021-04-01

Review 2.  The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects.

Authors:  Paul Declerck; Romano Danesi; Danielle Petersel; Ira Jacobs
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

Review 3.  The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy.

Authors:  Eva Rahman Kabir; Shannon Sherwin Moreino; Mohammad Kawsar Sharif Siam
Journal:  Biomolecules       Date:  2019-08-24

4.  Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and Physicians.

Authors:  Jingyan Yang; Kelly Blinzler; Joshua Lankin; Sapna Vijayakumar; Martine C Maculaitis; Ahmed Shelbaya
Journal:  BioDrugs       Date:  2021-11-25       Impact factor: 5.807

Review 5.  Practical Strategies for Advanced Practitioners Streamlining the Integration of Oncology Biosimilar Therapies Into Practice.

Authors:  Kelley D Mayden; John M Kelton; Joanne C Ryan; Ali McBride
Journal:  J Adv Pract Oncol       Date:  2022-06-21

6.  Considerations for the US health-system pharmacist in a world of biosimilars.

Authors:  Andrea Zlatkus; Todd Bixby; Kavitha Goyal
Journal:  Drugs Context       Date:  2020-02-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.